D. E. Shaw & Co. Inc. Grows Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

D. E. Shaw & Co. Inc. lifted its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 132.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,560,410 shares of the biopharmaceutical company's stock after purchasing an additional 889,968 shares during the quarter. D. E. Shaw & Co. Inc. owned about 0.52% of Amicus Therapeutics worth $14,699,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the company. Park Avenue Securities LLC purchased a new stake in Amicus Therapeutics during the fourth quarter worth approximately $123,000. Avanza Fonder AB purchased a new stake in Amicus Therapeutics during the 4th quarter worth $157,000. KBC Group NV boosted its position in Amicus Therapeutics by 44.4% during the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock worth $96,000 after purchasing an additional 3,120 shares during the period. R Squared Ltd acquired a new stake in Amicus Therapeutics in the 4th quarter valued at $79,000. Finally, China Universal Asset Management Co. Ltd. raised its position in Amicus Therapeutics by 11.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 63,358 shares of the biopharmaceutical company's stock valued at $597,000 after purchasing an additional 6,314 shares during the period.

Amicus Therapeutics Trading Down 3.1%

FOLD opened at $6.02 on Wednesday. Amicus Therapeutics, Inc. has a 12-month low of $5.82 and a 12-month high of $12.65. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. The stock has a market capitalization of $1.85 billion, a PE ratio of -33.44, a P/E/G ratio of 1.51 and a beta of 0.64. The firm's fifty day moving average price is $7.53 and its 200 day moving average price is $9.01.

Analysts Set New Price Targets

A number of research firms have recently issued reports on FOLD. The Goldman Sachs Group lowered their target price on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. UBS Group lifted their price objective on shares of Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Cantor Fitzgerald reissued an "overweight" rating and set a $21.00 target price on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Finally, StockNews.com downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat, Amicus Therapeutics has an average rating of "Moderate Buy" and an average target price of $16.22.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.